Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 clinical trial of OB-002H

Trial Profile

A phase 1 clinical trial of OB-002H

Planning
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs OB 002H (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Jan 2019 According to an Orion Biotechnology media release, the company plans to submit a regulatory filing in Q1 2019 to support initiation of this study in Q3 2019.
    • 09 Nov 2018 New trial record
    • 31 Oct 2018 According to an Orion Biotechnology media release,clinical study design was appropriate and met MHRA requirements. Company is preparing for clinical trial application (CTA) to be submitted and looking forward to receive feedback from the Polish National Regulatory authority.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top